Court rejects Novo bid to block Lilly obesity drug ads
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Eli Lilly reports promising lung cancer drug results seekingalpha.com